Montagu Evans Chooses MobileIron Cloud to Keep Client Data Safe on Mobile Devices
MobileIron (NASDAQ:MOBL), the secure foundation for modern work, today announced that Montagu Evans has selected MobileIron unified endpoint management (UEM) cloud solution, including MobileIron Access and MobileIron Threat Defense.
For nearly a century, Montagu Evans, a partnership and one of UK’s largest owner-managed surveying firms, has helped its clients shape some of UK’s largest commercial, residential and mixed-use property development projects. With increasingly sensitive client work, more employees on job sites using mobile devices, and the newly enforced GDPR, it was imperative for Montagu Evans to use a best-in-class UEM solution to securely manage all data without compromising productivity.
Safety from Mobile Threats
Since Montagu Evans’ employees often need to connect through unsecured networks, such as public Wi-Fi networks, the company needed to ensure that highly sensitive customer information could not be intercepted or compromised. To solve this problem, Montagu Evans chose MobileIron Threat Defense to work seamlessly in the background to detect and remediate threats without the employees needing to take any action on their part. Using MobileIron Threat Defense, Montagu Evans can keep client information safe on any device and any network that the employees use, no matter where they work.
“MobileIron is the perfect solution to meet the demands of our ongoing progressive IT strategy, significantly improving our cyber security posture,” said Mark Sedgwick, head of IT, Montagu Evans. “With MobileIron, we have the peace of mind that our company’s and our customers’ data are always protected no matter where our employees are.”
Need for Secure Access to Cloud Apps
Montagu Evans’ employees use a number of mobile applications to get their job done and MobileIron Access allows the employees to download and access all business and productivity applications on the go, knowing that it’s all done in a secure and protected environment.
“Montagu Evans is at the forefront of the many transformations that the real estate industry is undergoing,” said Vijay Pawar, VP of product management, MobileIron. "We are happy to be a part of the company’s commitment to working with a best-in-class UEM solution, bringing security and peace of mind to Montagu Evans’ employees and clients.”
About Montagu Evans
For nearly a century, Montagu Evans has helped its clients shape some of the UK’s largest commercial, residential and mixed-use property development projects. Our unique partnership structure allows us greater flexibility to put our most senior and experienced people on every job, meaning we can put our clients’ needs first – that is why we continue to remain a partnership and one of the UK’s largest owner-managed surveying firms.
For more information, please visit: http://www.montagu-evans.co.uk
About MobileIron
MobileIron provides the secure foundation for modern work. For more information, please visit: www.mobileiron.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181217005173/en/
Contact information
Marjaneh Ravai
MobileIron
mravai@mobileiron.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 202531.5.2025 15:00:00 EEST | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today will present new data from the Arm C and D cohorts of the pivotal, global Phase 3 SEQUOIA trial of BRUKINSA® (zanubrutinib). The findings underscore the strong and consistent efficacy of BRUKINSA across CLL patient types, including high-risk mutation status. These data will be presented in two rapid oral presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Data from the Arm D of SEQUOIA demonstrate that treatment with BRUKINSA plus venetoclax has the potential to drive progression-free survival and overall deep and durable responses across the frontline CLL patient spectrum, including patients with high-risk mutational status. The best undetectable minimal residual disease (uMRD) rate in peripheral blood at a sensitivity level 10-4 was 59%. These efficacy responses observed in Arm D, despite the high proportion of high-risk patients enrolled, are in
You Up? Grindr’s “Right Now” Goes Global30.5.2025 16:00:00 EEST | Press release
Grindr, the Global Gayborhood in Your Pocket™ with more than 14.6M average monthly active users, today announced the global launch of Right Now, their newest intent-based feature designed to instantly connect people looking for immediate encounters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250530651954/en/ Grindr's Right Now feature. Right Now is a real-time feed—separate from the app’s main grid that displays profiles—where Grindr users can post text and share photos displayed for one hour, letting other like-minded users know exactly what they’re looking for. “Right Now empowers our users to find exactly what they want, when they want it – without the guesswork,” said AJ Balance, Chief Product Officer at Grindr. “We built this intention-based feature based on feedback from our community so they can connect with like-minded people without wasting time on mismatched expectations. The response to our initial March launc
CAR T Vision Coalition Launches with Ambitious Goal to Double Patients Treated with the Curative Potential of CAR T-cell Therapy by 203030.5.2025 15:00:00 EEST | Press release
Today an international coalition announces the launch of CAR T Vision to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy. By 2030, the aim is to double the proportion of eligible patients treated with CAR T-cell therapy. As outlined in the new roadmap report, the coalition will work to address access challenges and drive meaningful change in the CAR T-cell therapy healthcare ecosystem with a focus on three critical priorities: increasing awareness and understanding of CAR T-cell therapy; expanding resources and capacity to deliver CAR T-cell therapy; and developing sustainable and innovative financing approaches to manage the costs of treatment and care. “Despite CAR T-cell therapy being available in the United States for nearly seven years in large B-cell lymphoma, only approximately two out of 10 eligible patients with some advanced blood cancers ever receive CAR T-cell therapy,” said Miguel Perale
Indian Educationist Dr. Achyuta Samanta Recognised With Research Institute in His Name at CUNY, USA30.5.2025 12:17:00 EEST | Press release
In a noteworthy development underscoring growing academic collaboration between India and the United States, the City University of New York (CUNY) has launched a dedicated research platform—the Achyuta Samanta India Initiative of the CUNY CREST Institute (ASIICCI). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529012005/en/ Dr. Milton Santiago, President of Bronx Community College, and Dr. Achyuta Samanta, Founder of KIIT & KISS, jointly inaugurate the Achyuta Samanta India Initiative of CUNY CREST Institute (ASIICCI) with a ribbon-cutting ceremony in New York. Named after Dr. Achyuta Samanta, a noted Indian educationist and social worker, the initiative focuses on academic research in Indian social and educational sectors, with a particular lens on Odisha. This marks one of the rare instances of a living Indian being honoured with such a naming in an American public university system. Dr. Samanta, who hails from Odisha
FDA Grants De Novo Clearance for Reflow Medical's Spur ® Peripheral Retrievable Stent System30.5.2025 07:08:00 EEST | Press release
Reflow Medical, Inc., a leading developer of innovative medical devices focused on complex cardiovascular disease, announced that the U.S. Food and Drug Administration (FDA) has granted De Novo clearance for the company’s Spur Peripheral Retrievable Stent System, a unique clinical solution for the treatment of de novo or restenotic lesions following predilatation in patients with infrapopliteal arterial disease. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529610368/en/ The first and only retrievable stent system that features a self-expanding stent with an integrated dilatation balloon catheter on an over-the-wire system. It is designed for controlled lesion penetration and treatment through a series of radially expandable spikes. Known as Retrievable Scaffold Therapy (RST), the spikes on the Spur Stent penetrate the lesion to increase the acute luminal diameter and modify the lesion morphology to change vessel complia
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom